e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Cystic fibrosis: basic and applied science
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers
S. Byrne, D. Jeffrey, R. Hatley (Chichester, United Kingdom)
Source:
Annual Congress 2013 –Cystic fibrosis: basic and applied science
Session:
Cystic fibrosis: basic and applied science
Session type:
Poster Discussion
Number:
2117
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Byrne, D. Jeffrey, R. Hatley (Chichester, United Kingdom). Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers. Eur Respir J 2013; 42: Suppl. 57, 2117
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Delivery of dornase alfa via breath-actuated nebulizer: In-vitro measures of performance
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012
Delivered dose of colistimethate sodium via 3 nebulizers; a comparison of bioassay and HPLC assay results
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics
Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques
Year: 2016
Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 503s
Year: 2003
Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 476-486
Year: 2013
Study of adherence to the use of inhaled sodium colistimethate through the I-neb® nebulization system
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Delivery efficiency of electronic and jet nebulisers aerosolising a colistimethate sodium solution
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation
Source: Eur Respir J 2011; 38: 1328-1335
Year: 2011
Effect of device and formulation on delivery of budesonide suspensions by nebulizers
Source: Eur Respir J 2002; 20: Suppl. 38, 542s
Year: 2002
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017
Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM)
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006
Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Effect of I:E ratio on the respirable delivered dose from nebulizers
Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept